<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02613195</url>
  </required_header>
  <id_info>
    <org_study_id>RenJiH-20151020</org_study_id>
    <nct_id>NCT02613195</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Hydrogen-Rich Celsior Solution Applied in Aging DBD Liver/Kidney Transplantation</brief_title>
  <acronym>HRCSDBD</acronym>
  <official_title>Hydrogen-Rich Celsior Solution Improve the Quality of Aging DBD Grafts in Liver/Kidney Transplantation: Prospective, Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RenJi Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether hydrogen-rich Celsior solution improve
      the quality of aging grafts in liver/kidney transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The organ shortage has been rising to impede the development of organ transplantation.To find
      a solution, transplantation center is working on the application of marginal grafted liver or
      renal, especially the aging grafts. The most common inducement of organ dysfunction during
      the perioperation is liver/renal ischemia-reperfusion (I/R) injury, caused by the generation
      of cytotoxic oxygen radicals. Hydrogen gas is a kind of reducing gas, which has been reported
      to display antioxidant properties and protective effects against organ dysfunction induced by
      various I/R injuries. Investigators will investigate whether hydrogen-rich Celsior solution
      improve the quality of aging grafts in liver/ kidney transplantation.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2016</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Aspartate Aminotransferase(AST)/Alanine Aminotransferase(ALT)</measure>
    <time_frame>up to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in direct bilirubin(DBil)/total bilirubin(TBil)</measure>
    <time_frame>up to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in creatinine</measure>
    <time_frame>up to 6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in glomerular filtration rate（GFR）</measure>
    <time_frame>up to 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pathological score of liver/kidney preservation injury during surgery</measure>
    <time_frame>during surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mitochondrial function index of hepatocyte/nephrocyte during surgery</measure>
    <time_frame>during surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The total incidence of adverse events/incidence of severe adverse events</measure>
    <time_frame>up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>postoperative complications</measure>
    <time_frame>up to 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Early graft function incidence</measure>
    <time_frame>baseline and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Graft dysfunction incidence</measure>
    <time_frame>baseline and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recipient survival</measure>
    <time_frame>baseline and 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Evidence of Liver Transplantation</condition>
  <arm_group>
    <arm_group_label>Hydrogen-rich Celsior solution</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Using aging liver grafts（≥60 years old)，lavaged and cold stored with hydrogen-rich Celsior solution for 2-4 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Celsior solution</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Using aging liver/kidney grafts（≥60 years old）, lavaged and cold stored with common Celsior solution for 2-4 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrogen-Rich Celsior Solution</intervention_name>
    <description>Before the procedure, add hydrogen gas into Celsior solution. After harvesting the liver/kidney grafts, lavage and cold store the grafts with Hydrogen-Rich Celsior Solution.</description>
    <arm_group_label>Hydrogen-rich Celsior solution</arm_group_label>
    <other_name>HR solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Donors:

          1. Age of the donor ≥60 yrs.

          2. The donor has no historical records of drug abuse, alcoholic abuse, homosexual,or drug
             addiction, etc.

          3. Evaluate infections and infectious disease of the donor.

          4. History of malignant tumor;

          5. History of hypertension, diabetes, hemophilia, or other anticoagulant disease,kidney
             donor should not have a history of kidney disease.

          6. Daily urine volume is approximately normal.

          7. Donor should be subjected to physical examination by medical doctor of OPO stuff
             before donation; the OPO stuff should realize whether the potential donor has infected
             lesion or not, such as abscess, ulcer, lymphadenectasis， etc., and evaluate infectious
             risk of recipient post-operationally.

          8. OPO stuff should realize the dynamic change of body temperature, as well as various
             intensive care parameters of the potential donor, it shall be very important to be
             sure whether the potential donor has pulmonary/ systemic infections or not,especially
             for whom has longer ICU duration (&gt; 7 Days).

          9. The potential donor should has a systolic blood pressure ≥ 50 mm Hg (1mmHg=0.133 kPa)
             and arterial SaO &gt; 80%.

         10. Liver Biochemistry: alanine aminotransferase (ALT) ≤ 6ULN, total bilirubin (TBil) ≤
             50umol/L;Kidney Biochemistry: serum creatinine (sCre) ≤ 2ULN;

         11. Negative anti-HIV antibody;

         12. Negative bacterial and fungal culture in blood;

         13. Ultrasonic diagnosis of fatty liver, trauma, hematoma, lithiasis, etc., as well as
             size of both kidney, hydronephrosis, nephrolithiasis, etc. if possible.

         14. Graft liver should be soft, normal color and even, no tumor or other
             abnormity;steatosis ≤ 30% by liver biopsy.Graft kidneys should have complete renal
             capsule with no congestion or bleeding;proximal tubular necrosis ≤ 50%, without
             obvious structural damage.Organ (liver and kidney) cold ischemia time (CIT) is
             determined as the time duration from cold preservation of organs to transplant
             re-perfusion. CIT of aging DBD liver and kidney graft should be ≤ 10 and16 hours,
             respectively.

        Recipients：

          1. Aged between 18-65 years old

          2. MELD score ≤25,BMI≤25

          3. Patients with tumor,the expected lifetime≥6 months

          4. Agree to anticipate the trial and sign the informed consent

        Exclusion Criteria:

          -  Donor's age ＜ 60 yrs;

          -  The donor has historical records of drug abuse, alcoholic abuse, homosexual, or drug
             addiction, etc.

          -  The donor is HIV infected, or has severe infection, or positive bacterial and/ or
             fungal culture results;

          -  Uncontrollable hypertension, diabetics;

          -  Malignant tumor;

          -  Unstable hemodynamic response or SaO status, such as systolic pressure ＜50 mm Hg
             (1mmHg=0.133 kPa) , or arterial SaO＜80%.

          -  Liver Biochemistry: alanine aminotransferase (ALT)＞6ULN, total bilirubin
             (TBil)＞50umol/L;

          -  Graft liver has a steatosis ＞30%, or graft kidney has a proximal tubular necrosis＞50%
             or obvious glomerular sclerosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xia Qiang, investigator</last_name>
    <role>Study Director</role>
    <affiliation>Deparment of Liver Surgery</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Xia Qiang, investigator</last_name>
    <phone>+86-21-68383775</phone>
    <email>xiaqiang@shsmu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xue Feng, investigator</last_name>
    <phone>+8613761267573</phone>
    <email>fengxue6879@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ren Ji Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Xia Qiang, Investigator</last_name>
      <phone>+86-21-68383775</phone>
      <email>xiaqiang@shsmu.edu.cn</email>
    </contact>
    <contact_backup>
      <last_name>Xue Feng, Investigator</last_name>
      <phone>+8613761267573</phone>
      <email>fengxue6879@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Xia Qiang, Investigator</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xue Feng, Investigator</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shi Shaojun</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Deparment of Liver Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University</name>
      <address>
        <city>Shanghai</city>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Abe T, Li XK, Yazawa K, Hatayama N, Xie L, Sato B, Kakuta Y, Tsutahara K, Okumi M, Tsuda H, Kaimori JY, Isaka Y, Natori M, Takahara S, Nonomura N. Hydrogen-rich University of Wisconsin solution attenuates renal cold ischemia-reperfusion injury. Transplantation. 2012 Jul 15;94(1):14-21. doi: 10.1097/TP.0b013e318255f8be.</citation>
    <PMID>22683850</PMID>
  </results_reference>
  <results_reference>
    <citation>Qian L, Shen J. Hydrogen therapy may be an effective and specific novel treatment for acute graft-versus-host disease (GVHD). J Cell Mol Med. 2013 Aug;17(8):1059-63. doi: 10.1111/jcmm.12081. Epub 2013 Jun 7.</citation>
    <PMID>23742028</PMID>
  </results_reference>
  <results_reference>
    <citation>Buchholz BM, Masutani K, Kawamura T, Peng X, Toyoda Y, Billiar TR, Bauer AJ, Nakao A. Hydrogen-enriched preservation protects the isogeneic intestinal graft and amends recipient gastric function during transplantation. Transplantation. 2011 Nov 15;92(9):985-92. doi: 10.1097/TP.0b013e318230159d.</citation>
    <PMID>21956195</PMID>
  </results_reference>
  <results_reference>
    <citation>Liu Y, Yang L, Tao K, Vizcaychipi MP, Lloyd DM, Sun X, Irwin MG, Ma D, Yu W. Protective effects of hydrogen enriched saline on liver ischemia reperfusion injury by reducing oxidative stress and HMGB1 release. BMC Gastroenterol. 2014 Jan 12;14:12. doi: 10.1186/1471-230X-14-12.</citation>
    <PMID>24410860</PMID>
  </results_reference>
  <results_reference>
    <citation>Noda K, Shigemura N, Tanaka Y, Bhama J, D'Cunha J, Kobayashi H, Luketich JD, Bermudez CA. Hydrogen preconditioning during ex vivo lung perfusion improves the quality of lung grafts in rats. Transplantation. 2014 Sep 15;98(5):499-506. doi: 10.1097/TP.0000000000000254.</citation>
    <PMID>25121557</PMID>
  </results_reference>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 24, 2015</study_first_submitted>
  <study_first_submitted_qc>November 20, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2015</study_first_posted>
  <last_update_submitted>November 20, 2015</last_update_submitted>
  <last_update_submitted_qc>November 20, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ischemia-Reperfusion Injury</keyword>
  <keyword>oxidative stress</keyword>
  <keyword>organ preservation</keyword>
  <keyword>Hydrogen</keyword>
  <keyword>Kidney Transplantation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

